Leading Chinese Healthcare Group Adopts Medidata's Cloud Technology
to Bring Operational Efficiencies to its R&D Programs
NEW YORK & SHANGHAI--(BUSINESS WIRE)--
(NASDAQ: MDSO), the leading global provider of cloud-based technology
and data analytics for clinical research, today announced an enterprise
agreement with leading Chinese healthcare group, Shanghai Fosun
Pharmaceutical (Group) Co., Ltd.'s subsidiary Shanghai Fosun
Pharmaceutical Development Co., Ltd.(Fosun Pharma). Fosun Pharma has
adopted the Medidata
Clinical Cloud® platform to improve data management capabilities and
bring operational efficiencies to its clinical studies in China.
Fosun Pharma is implementing Medidata Rave®, a unified EDC and CDMS
solution for capturing, managing and reporting patient data, across its
generics development pipeline, accelerating treatments in such
therapeutic areas as cardiovascular, oncology, anti-infection and
central nervous system (CNS). The leading Chinese clinical R&D company
is also leveraging Rave Study Design and Build Essentials (SDBE)
training. Taught on RaveX—the
latest version of Rave—SDBE will equip Fosun Pharma's study teams with
the fundamentals required to develop and update electronic Case Report
Forms (eCRFs), ultimately optimizing study implementation and ensuring
trail timelines are met.
"We are proud to be Fosun Pharma's cloud-based, clinical technology
platform of choice and a key addition to its roster of partners," said
Edwin Ng, Medidata's vice president of field operations, APeJ (Asia
Pacific except Japan). "We look forward to powering Fosun Pharma's
clinical studies with Medidata's flexible, cutting-edge technology as
they strive to become a first-class enterprise in the global healthcare
market and a key player in the bioequivalence space."
is reinventing global drug and medical device development by creating
the industry's leading cloud-based solutions for clinical research.
Through our advanced applications and intelligent data analytics,
Medidata helps advance the scientific goals of life sciences customers
worldwide, including over 850 global pharmaceutical companies, biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make more
informed decisions earlier and faster. Our unparalleled clinical trial
data assets provide deep insights that pave the way for future growth.
The Medidata Clinical Cloud is the primary technology solution powering
clinical trials for 18 of the world's top 25 global pharmaceutical
companies and is used by 18 of the top 25 medical device developers—from
study design and planning through execution, management and reporting.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170816006052/en/
D'Amico, +1 732-767-4331
Erik Snider, +1 646-362-2997
News Provided by Acquire Media